



11TH ANNUAL REPORT

2020-21

**NOVA HEALTH SCIENCES PRIVATE
LIMITED**



Corporate Information

Board of Directors:

Sambasivarao Yeluri
Malathi Siripurapu

Director
Director

Corporate Identity Number: U8S190TG2010PTC068S84

Registered Office

S.Y.No: 2,S L/A/1
Singannaguda Village
Mulugu Mandal
Siddipet District -S02279
Telengana

E-Mail: novahealthsciences789@gmail.com

Statutory Auditors:

M/s. NSVR and Associates LLP,
Chartered Accountants,
FRN: 008801S/S200060
Address: Plot No. 28, Flat No. 101,
Nestcon Gayatri, Road No. 10,
Banjara Hills, Hyderabad-S00034, Telangana.

NOVA HEALTH SCIENCES PRIVATE LIMITED

CIN: U85190TG2010PTC068584

R.O.: S.Y.No:2,5L/1,SINGANNAGUDA VILLAGE, MULUGU MANDAL, SIDDIPET DISTRICT -502279

NOTICE

Notice is hereby given that the 11th Annual General Meeting of the members of 'Nova Health Sciences Private Limited' ("The Company") will be held on Tuesday, the 30th day of November 2021, at 11.30 a.m. at its registered office situated at S.Y. No; 2,5L/A/1, Singannaguda Village, Mulugu Mandal, Siddipet District 502279 Telangana, for transacting the following business:

ORDINARY BUSINESS:

1. Adoption of Audited Financial Statements of the Company for the financial year ended 31st March, 2021 and the reports of the Auditors and Board of Directors thereon.


To consider and if thought fit, to pass with or without modification(s) the following resolution as an **Ordinary Resolution:**

"**RESOLVED THAT** pursuant to the provisions of section 129 and all other applicable provisions of the Companies Act, 2013 and Rules made there under the Audited Financial Statements of the Company for the financial year ended 31st March, 2021 together with the Report of the Board of Directors and the Auditors thereon, be and are hereby considered, approved and adopted."

"**RESOLVED FURTHER THAT** the Board of Directors be and are hereby authorized to do or cause to be done all such acts, deeds and things as may be required or considered necessary or incidental thereto for giving effect to the aforesaid resolution."

Order of the Board
For Nova Health Sciences Private Limited

Date: 29.11.2021
Place: Hyderabad


Sambasivarao Yeluri
Director
DIN: 02311336

NOVA HEALTH SCIENCES PRIVATE LIMITED

CIN: U85190TG2010PTC068584

R.O.: S.Y.No: 2,5 L/A/1,Singannaguda Village,Mulugu Mandal, Siddipet District-502279 Telangana.

DIRECTORS' REPORT

Your Directors have pleasure in presenting the **11th (ELEVENTH) ANNUAL REPORT** on the business and operations of the Company together with the Audited Financial Statements for the Financial Year ended March 31, 2021

FINANCIAL PERFORMANCE:

(Values in Rs.)

Particulars	Year Ended March 31, 2021	Year Ended March 31, 2020
Income from Operations	167,109	158,100
Other income	0	0
Total income	167,109	158,100
Total Expenditure	262,537	153,390
Profit Before Tax	(95,428)	4,710
Less: Tax expenses	0	0
Net Profit/Loss	(95,428)	4,710

SUMMARY OF OPERATIONS & STATE OF COMPANY'S AFFAIRS:

During the financial year under review your company recorded a Loss for the FY 2020-21 Rs.- 95,428 as against a Profit of Rs. **4710/-** for the FY 2019-20. The affairs of the Company are conducted in accordance with the accepted business practices and within the purview of the applicable legislations.

SUBSIDIARY COMPANIES/JOINT VENTURES/ASSOCIATE COMPANIES:

The Company does not have any Subsidiary Company, Joint Ventures. During the year under review no Company has become/ceased to be its Subsidiary, Joint Venture or Associate of Company.

SHARE CAPITAL:

The paid- up Equity Share Capital as at March 31, 2021 stood at Rs. 1,00,000/-. During the year, under review, there is no change in the capital structure of the company.

CHANGE IN THE NATURE OF BUSINESS

There is no change in the nature of the business during the financial year under review.

DIVIDEND:

The Board of directors do not recommend any Dividend for the year under review.

TRANSFERS TO RESERVES:

During the year under review, the company has transferred Loss of Rs. 95,428 to reserves and Surplus for the financial year 2020-21.

MATTERS RELATED TO DIRECTORS AND KEY MANAGERIAL PERSONNEL:

During the year under review, there was no change in the composition of the Board of Directors.

KEY MANAGERIAL PERSONNEL:

During the year under review, the company is not mandated to appoint any Key Managerial Person.

NO. OF BOARD MEETINGS HELD DURING THE YEAR:

The Board of Directors duly met 6 (Six) times and in respect of which meetings, proper notices were given and the proceedings were properly recorded.

DIRECTORS' RESPONSIBILITY STATEMENT:

Based on the framework of internal financial controls and compliance systems established and maintained by the Company, work performed by the Internal, Statutory Auditors and the reviews performed by Management and the Board, the Board is of the opinion that the Company's internal financial controls were adequate and effective during the financial year 2020-21.

Accordingly, pursuant to Section 134 (3) (c) and 134 (5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that:

- i. In the preparation of the annual accounts for the year ended March 31, 2021, the applicable accounting standards have been followed and there are no material departures;
- ii. Accounting policies have been selected and applied consistently and judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company as at FY ended March 31, 2021 and of the profit and loss of the Company for that period on that date;
- iii. Proper and sufficient care have been taken for the maintenance of accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company, for preventing & detecting fraud and/or other irregularities;

- iv. The annual accounts have been prepared on a going concern basis;
- v. Internal financial controls have been laid down by the Company and that such internal financial controls are adequate and are operating effectively; and
- vi. Proper systems have been devised to ensure compliance with the provisions of all applicable laws and such systems are adequate and operating effectively.

STATUTORY AUDITORS:

Pursuant to Section 139, 141 & 142, and other applicable provisions, if any, of the Companies Act, 2013, M/s. NSVR & ASSOCIATES LLP, Chartered Accountants (Firm Registration No. 008801S/S200060) were re-appointed by the Shareholders of the Company as Statutory Auditors of the Company to hold office from the conclusion of the 9th Annual General Meeting of the Company to the conclusion of the 14th Annual General Meeting to conduct the Statutory Audit of the Company for the financial years commencing from 2019-20 to 2023-24.

REPLIES TO THE STATUTORY AUDITOR'S REMARKS

The Auditors Report for the financial year ended 31st March, 2021 does not contain any qualification, adverse remark or reservation and therefore, do not call for any further explanation or comments from the Board under Section 134 (3) of the Companies Act, 2013.

FRAUDS REPORTED BY THE AUDITORS

There are no frauds reported by auditors under sub-section (12) of section 143.

COST RECORDS/ COST AUDIT

As per the criteria laid down in Section 148 of the Act read with the Companies (Cost Records and Audit) Rules, 2014 as amended from time to time, your Company is not required to maintain of cost records and accordingly cost audit is not applicable to your company.

PUBLIC DEPOSITS

During the Financial Year 2019-20, your Company has not accepted/ not required to renew any deposit that falls within the meaning of Section 73 and 74 of the Companies Act, 2013.

PARTICULARS OF LOANS, GUARANTEES, INVESTMENTS UNDER SECTION 186:

During the year under review, the Company has not given any loan/ provided guarantee/ made any investments as specified under the provisions of section 186 of the Companies Act, 2013.

MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There have been no material changes and commitments, affecting the financial position of the Company which have occurred during/ after the balance sheet date till the date of this directors' report.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY REGULATORS OR COURTS OR TRIBUNALS

During the Financial year under review, no significant and material orders passed by regulators or courts or tribunals impacting the going concern status and company operations in future.

RISK MANAGEMENT FRAMEWORK:

The Company has a robust internal business management framework to identify, evaluate business risks and opportunities which seeks to minimize adverse impact on the business objectives and enhance the Company's business prospects.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

During the year under review, there were no contracts or arrangements entered with related parties. For the details of related party transactions for the FY 2020-2021 please refer notes to audited financial statements.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

Conservation of energy:

The operations of the Company are not energy-intensive. However, The Company is making continuous efforts on ongoing basis to conserve the energy by adopting innovative measures to reduce wastage and optimize consumption.

	The steps taken or impact on conservation of energy	The operations of the company are not energy intensive, adequate measures have, however, been taken, to conserve and reduce wastage and optimize consumption.
	The steps taken by the company for utilizing alternate sources of energy	
	The Capital investment on energy conservation equipment's	Nil

Technology Absorption: Nil

Foreign Exchange Earnings & Outgo: Nil

(Amount in Rs.)

Particulars	2020-21	2019-20
Foreign Exchange earnings	0	0
Foreign Exchange outgo	0	0

CORPORATE SOCIAL RESPONSIBILITY (CSR)

Pursuant to Section 135 and Schedule VII of the Companies Act, 2013, the company do not fall under the class of companies as provided in the Act, hence, provisions of CSR shall not apply to the company.

PARTICULARS OF EMPLOYEES

There is no Employee drawing remuneration aggregating to the limits prescribed under the provisions of Section 134(3)(q) of the Companies Act, 2013 read with Rule 5(2) the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

INTERNAL FINANCIAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The management has established and maintaining adequate internal financial controls to ensure orderly and efficient conduct of its business including adherence to company's policies to safeguard its assets, prevent and detect frauds and errors, check the accuracy and completeness of accounting records and prepare financial information.

RISK MANAGEMENT POLICY

The Company has developed and implemented a risk management policy which identifies major risks which may threaten the existence of the Company. The same has also been adopted by your Board and is also subject to its review from time to time. Risk mitigation process and measures have been also formulated and clearly spelled out in the said policy.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

The following is a summary of sexual harassment complaints received and disposed off during each Calendar year:


- No. of complaints received : Nil
- No. of complaints disposed off : Nil

APPRECIATION:

The Directors express their appreciation to all employees of the various divisions for their diligence and contribution to performance. The Directors also record their appreciation for the support and co-operation received from bankers and all other stakeholders. Last but not the least, the Directors wish to thank all shareholders for their continued support.

By Order of the Board
For Nova Health Sciences Private Limited

Date: 29.11.2021
Place: Hyderabad


Sambasivarao Yeluri
Director
DIN: 02311336


Malathi Siripurapu
Director
DIN: 03033944



INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF NOVA HEALTH SCIENCES PRIVATE LIMITED

Report on the Audit of the Financial Statements Opinion:

We have audited the accompanying financial statements of **Nova Health Sciences Private Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2021, and the Statement of Profit and Loss for the year ended on that date, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, the profit for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to be communicated in our audit report.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexure to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards referred to in Section 133 of Companies Act 2013. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our responsibility is to express an opinion on these financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the Accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication





Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016, issued by the department of company affairs, in terms of section 143 (11) of the companies Act, 2013, and on the basis of our examination of the books and records as we considered appropriate and according to the information and explanation given to us.

2. As required by section 143(3) of the Companies Act 2013, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.

b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.

c) The Balance Sheet and Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid financials comply with the Accounting Standards specified under of Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.

e) On the basis of written representations received from the directors as on March 31, 2021, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021, from being appointed as a director in terms of sub section (2) of section 164 of the Companies Act, 2013.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, and to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively throughout the period of audit

g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i) There are no pending litigations for or against the Company which would impact its financial position.

ii) The Company does not have any derivatives contracts. Further there are no long term contracts for which provisions for any material foreseeable losses is required to be made.

iii) There are no amounts pending that are required to be transferred to Investor Education and Protection Fund.

For NSVR & ASSOCIATES LLP.,
Chartered Accountants
(FIRN No.008801S/S200060).



P Venkata
Partner
M.no:230675
UDIN: 22230675ACZ11WU1689

Date: 29/11/2021
Place: Hyderabad.

NOVA HEALTH SCIENCES PRIVATE LIMITED
2-1-107/04, BEHIND NOBLE ENCLAVE KOMPALLY QUTHBULLAPUR SECUNDERABAD HYDERABAD 500014
BALANCE SHEET AS ON 31st MARCH, 2021

PARTICULARS	Notes	As At 31.03.2021	As At 31.03.2020
I. EQUITY AND LIABILITIES :			
1. Shareholders Funds :			
(a) Share Capital	1	1,00,000	1,00,000
(b) Reserves And Surplus	2	(1,25,842)	(30,414)
2. Share Application Money Pending Allotment :			
3. Non Current Liabilities :			
(a) Long Term Borrowings	3	2,03,631	25,500
(b) Deferred Tax Liability		-	
4. Current Liabilities :			
(a) Short Term Borrowings			
(b) Trade Payables	4	12,30,649	3,96,995
(c) Short Term Provisions			
(d) Other Current Liabilities	5	49,682	49,682
TOTAL		14,58,123	5,41,763
II. ASSETS :			
1. Non-Current Assets :			
(a) Fixed Assets			
i) Tangible Assets			
(b) Non current investments			
(c) Deferred tax assets (net)			
(d) Long term loans and advances			
(e) Other Non Current Assets			
2. Current Assets :			
(a) Inventories	6	9,32,383	2,65,838
(b) Trade Receivables	7	1,31,308	1,66,007
(c) Cash And Cash Equivalents	8	3,02,090	17,576
(d) Short Term Loans And Advances	9	79,680	79,680
(e) Other Current Assets	10	12,662	12,662
TOTAL		14,58,123	5,41,763

SIGNIFICANT ACCOUNTING POLICIES & NOTES

In terms of our report attached.
For NSVR & ASSOCIATES LLP
Chartered Accountant
FRN: 008801S/S200060

For and on behalf of the Board of Directors
NOVA HEALTH SCIENCES PRIVATE LIMITED

VENKATA
Partner
Membership No. 22230673
DIN: 02230673



J. Sambasivarao
SAMBASIVARAO YELURI
DIRECTOR
DIN No. 02311336

S. Malathi
MALATHI SIRIPURAPU
DIRECTOR
DIN No. 03033944

Place: Hyderabad
Date: 29/11/2021

NOVA HEALTH SCIENCES PRIVATE LIMITED
2-1-107/04, BEHIND NOBLE ENCLAVE KOMPALLY QUTHIBULLAPUR SECUNDERABAD HYDERABAD 500014
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31-03-2021

Particulars	Notes	2020-21	2019-20
I. Revenue from operations	11	1,67,109	1,58,100
II. Other income		-	-
III. Total Revenue (I + II)		1,67,109	1,58,100
IV. Expenses:			
Purchases	12	8,33,654	3,76,428
Changes in inventories of finished goods work-in-progress and Stock in-Trade	13	(6,66,545)	(2,65,838)
Employee benefits expense		-	-
Finance costs		-	-
Operating Expenses		-	-
Depreciation and amortization expense		-	-
Other expenses	14	95,428	42,800
Total expenses		2,62,537	1,53,390
Profit before exceptional and extraordinary items and tax (III-IV)		(95,428)	4,710
VI. Exceptional items (Prior Period Item)		-	-
VII. Profit before extraordinary items and tax (V - VI)		(95,428)	4,710
VIII. Extraordinary Items		-	-
IX. Profit before tax (VII- VIII)		(95,428)	4,710
X. Tax expense:			
(1) Current tax		-	-
(2) Deferred tax Liability		-	-
Profit (Loss) for the period from continuing operations (VII-VIII)		(95,428)	4,710
XII Profit/(loss) from discontinuing operations		-	-
XIII Tax expense of discontinuing operations		-	-
Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		(95,428)	4,710
XV Profit (Loss) for the period (XI + XIV)		(95,428)	4,710
XVI Earnings per equity share:			
(1) Base		(9.54)	0.47
(2) Diluted		(9.54)	0.47
SIGNIFICANT ACCOUNTING POLICIES & NOTES	A		

For NSVR & ASSOCIATES LLP
Chartered Accountant
FRN: 008801S/S200060

Pooja

VENKATARAMAN
Partner
Membership No. 1111111111
UDIN : 22230675ACZ11WU1689

Place: Hyderabad
Date: 29/11/2021

For and on behalf of the Board of Directors of
NOVA HEALTH SCIENCES PRIVATE LIMITED

S. Sambasivarao Yeluri
SAMBASIVARAO YELURI
Director
DIN: 02311336

S. Malathi
MALATHI SIRIPURAPU
Director
DIN: 03033944

NOTE 1 : SHARE CAPITAL

A) Details of the Authorized, Issued, Subscribed and Paid up share capital have been depicted in the table below :

Particulars	31 March, 2021		31 March, 2020	
	Number of shares	Amount	Number of shares	Amount
(a) Authorised 10,000 Equity shares of Rs.10/- each with voting	10,000	100,000	10,000	100,000
(b) Issued, Subscribed and Paid up 10,000 Equity shares of Rs.10/- each with voting	10,000	100,000	10,000	100,000
Total	10,000	100,000	10,000	100,000

B) Reconciliation of shares outstanding at the beginning and at the end of the reporting period

Particulars	31 March, 2021		31 March, 2020	
	Number of shares	Amount	Number of shares	Amount
No. of Equity shares outstanding at the beginning	10,000	100,000	10,000	100,000
Add : Shares allotted during the year	-	-	-	-
Less: Shares bought back during the period	-	-	-	-
No. of Equity shares outstanding at the End of	10,000	100,000	10,000	100,000

C) List of Shareholders holding more than 5% share capital

Name of Shareholders	31 March, 2021		31 March, 2020	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
a) Yeluri Sambasiva Rao	8,000	80	8,000	80
b) Y. Malathi	2,000	20	2,000	20
TOTAL	10,000	100	10,000	100

Terms and rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10/- per share. Each holder of equity shares is entitled to one vote per share. No dividend was proposed by the Board of Directors during the year.



Y. Sambasiva Rao



NOTES FORMING PART OF THE BALANCE SHEET

NOTE - 2 : RESERVES & SURPLUS

Particulars	F.Y 2020-21	F.Y 2019-20
Surplus :		
Opening Balance	(30,414)	(35,124)
Add : Net Profit / (Loss)	(95,428)	4,710
TOTAL	(125,842)	(30,414)

NOTE - 3 : LONG TERM BORROWINGS

Particulars	F.Y 2020-21	F.Y 2019-20
Loans from related parties	203,634	25,500
Total	203,634	25,500

NOTE - 4 : TRADE PAYABLE

Particulars	F.Y 2020-21	F.Y 2019-20
SUNDRY CREDITORS	1,230,649	396,995
Total	1,230,649	396,995

NOTE - 5 OTHER CURRENT LIABILITIES

Particulars	F.Y 2020-21	F.Y 2019-20
Audit Fee Payable	49,682	49,682
Total	49,682	49,682



NOTE -6 INVENTORIES

Particulars	F.Y 2020-21	F.Y 2019-20
Stock	932,383	265,838
Total	932,383	265,838

NOTE 7 -TRADE RECEVIBLES

Particulars	F.Y 2020-21	F.Y 2019-20
SUNDRY DEBTORS	131,308	166,007
Total	131,308	166,007

NOTE 8 - CASH AND CASH EQUIVALENTS


Particulars	F.Y 2020-21	F.Y 2019-20
Cash on hand	10,078	17,196
bank	292,012	380
Total	302,090	17,576

NOTE -9 SHORT TERM LOANS AND ADVANCES

Particulars	F.Y 2020-21	F.Y 2019-20
Other loans and advances	79,680	79,680
Total	79,680	79,680

NOTE -10 OTHER CURRENT ASSETS

Particulars	F.Y 2020-21	F.Y 2019-20
Balance with Revenue Authorities	12,662	12,662
Total	12,662	12,662



NOVA HEALTH SCIENCES PRIVATE LIMITED
NOTES FORMING PART OF STATEMENT OF PROFIT AND LOSS

NOTE - 11 : REVENUE FROM OPERATIONS

Particulars	F.Y 2020-21	F.Y 2019-20
Sale of Services	167,109	158,100
Total	167,109	158,100

NOTE - 12 PURCHASES


Particulars	F.Y 2020-21	F.Y 2019-20
Purchases	833,654	376,428.00
Total	833,654	376,428.00

NOTE - 13: CHANGE IN INVENTORIES

Particulars	F.Y 2020-21	F.Y 2019-20
Opening Stock of Inventory	265,837.8	-
Closing Stock of Inventory	932,382.8	265,838
Total	(666,545)	265,838

NOTE - 14 : OTHER EXPENSES

Particulars	F.Y 2020-21	F.Y 2019-20
Marketing expense	44,200	-
Internet charges	4,130	-
Misc Expense	16,500	-
Late fee	23,480	-
Office Expenses	-	35,682
Audit Fees	7,000	7,000
bank charges	118	118
Total	95,428	42,800



NOVA HEALTH SCIENCES PRIVATE LIMITED: Financial Year 2020-21
NOTES forming part of the Financial Statements

Note A Significant Accounting Policies

1. Corporate Information:

NOVA HEALTH SCIENCES PRIVATE LIMITED is registered as a Private Limited Company under the Companies Act 1956 in the state of Telangana. The Corporate Identification number of the company is U85190TG2010PTC068584 was registered on 25th May, 2010.

2. Basis of preparation of financial Statements:

The Financial statements have been prepared in accordance with the generally accepted accounting principles and in India (Indian GAAP) to comply with the Accounting standards specified in section 133 of the companies Act, 2013 and the relevant provisions of the Act as applicable. The Financial Statements of the company are prepared under historical cost convention using the accrual method of accounting.

All assets and liabilities have been classified as current or non-current as per the operating cycle criteria set out in the Revised Schedule III to the Companies Act, 2013.

3. The Company's Summarized Significant accounting policies are stated below -

A. Use of Estimates:

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets, and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known/ materialized.

B. Fixed Assets:

Fixed assets are recognized at cost of acquisition and installation less accumulated depreciation. The cost comprises purchase price, freight, duties, levies, borrowing cost and directly attributable cost of bringing the assets to their working condition for intended use as per the accounting Standard 10 "accounting for fixed assets". Subsequent expenditure related to an item of fixed assets is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance or extend its estimated useful life.



NOTES forming part of the Financial Statements

C. Revenue Recognition:

Revenue is recognized on the basis of invoice raised or receipt of revenue whichever is earlier.

D. Taxation:

i) Current Tax:

Current tax expenses are accounted in the same period to which the revenue and expenses relate. Provision for current income tax is made for the tax liability payable on taxable income after considering tax allowances, deductions and exemptions determined in accordance with the applicable tax rates and the prevailing tax laws.

ii) Deferred Tax:

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period and which are capable of reversal in one or more subsequent period(s) is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is virtual certainty with respect to the reversal of the same in future years. Deferred tax assets are reviewed at each balance sheet date and are written-down or written-up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realized.

E. Earnings per share:


Basic Earnings per Share is calculated by dividing the net earnings after tax for the year attributable to equity shareholders by weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share net profit or loss for the year attributable to equity shareholders and weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

F. Provisions and Contingent Liabilities

Provisions: Provisions are recognized when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance Sheet date and are not discounted to its present value.

G. Cash and Cash Equivalents:

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.



NOTES forming part of the Financial Statements

Cash and Cash equivalents for the purpose of cash flow statement comprise cash at bank and in hand and short term investments with an original maturity of not more than three months.

Disclosures Required by Accounting Standards:



J. Sambasiva Rao



NOTES forming part of the Financial Statements

H. Other Disclosures:**(i) Earnings Per Share :**


Particulars	As at 31.03.2021	As at 31.03.2020
a. Net Profits Attributable to Equity Shareholders	(95,428)	4,710
b. Weighted Average No of Equity Shares Outstanding during the Year	10,000	10,000
c. Add: Dilutive effect of potential ordinary Shares outstanding	NIL	NIL
d. Weighted average number of Ordinary shares in computing diluted earnings per share	10,000	10,000
Earnings per Share for the face value of Rs.10		
- Basic (a/b)	(9.54)	0.47
- Dilutive(a/d)	(9.54)	0.47

(ii) Related Party Disclosure:**Related parties:**

Name of the Related Party	Nature of Relationship
Sambasiva Rao Yeluri	Director
Malathi Siripurapu	Director

Directors/KMP:

Particulars	31.03.2021	31.03.2020
Salary/Remuneration	-	-
Advances given by Company		
Opening Balance	-	-
Transactions during the year	-	-
Closing Balance	-	-
Advances taken by Company		
Opening Balance	-	-
Transactions during the year	-	-
Closing Balance	-	-



NOVA HEALTH SCIENCES PRIVATE LIMITED: Financial Year 2020-21
NOTES forming part of the Financial Statements

(iii) Remuneration to Statutory Auditor:


Particulars	For the year ended March 31,	For the year ended March 31,
	2021	2020
Audit Fees	7,000	7,000
Total	7,000	7,000

For NSVR & ASSOCIATES LLP.
Chartered Accountants
FRNo.008801S/S200060

On & behalf of Board of directors
Nova Health Sciences Private Limited



P. Venkata
Partner
Membership No. 40675
UDIN: 22230675ACZHWU1689


Samba Siva Rao Yeluri
Director
(DIN:02311336)

Place: Hyderabad
Date : 29/11/2021


Malathi Sripurapu
Director
(DIN:03033944)